Posted by admin on Apr 30, 2025 in |
Extrapulmonary tuberculosis (EPTB) accounts for a significant proportion of TB infections worldwide; however, its diverse clinical manifestations and tissue-specific involvement make diagnosis and treatment challenging. Recent years have seen substantial improvements in both the diagnosis and treatment of EPTB. Bedaquiline, delamanid, and pretomanid have revolutionized the treatment of multidrug-resistant and extensively drug-resistant tuberculosis. These drugs, often used in combination, enhance outcomes for both pulmonary and extrapulmonary diseases. Corticosteroids, immunomodulators like interferon-gamma, and vitamin D supplements effectively reduce inflammation and boost the immune response in severe cases of tuberculosis meningitis or pericarditis. Advanced drug delivery technologies, such as nanoparticles and liposomes, can improve drug bioavailability and target affected areas while minimizing overall toxicity. In resource-limited settings, the Directly Observed Treatment, Short-course (DOTS) strategy helps improve treatment adherence and outcomes. Future goals include personalizing drug regimens based on genetic and resistance profiles and developing shorter, less toxic treatment protocols. Expanding molecular diagnostic tools and laboratory capacity will enhance early detection and treatment. These advancements in EPTB management are expected to improve...
Read More
Posted by admin on Apr 30, 2025 in |
Transthyretin is essential for transporting retinol and thyroxine, produced mainly in the liver. TTR amyloidosis occurs when misfolded TTR aggregates form amyloid fibrils, leading to organ dysfunction. FAP (Familial amyloid polyneuropathy linked to mutations like the V30M variant, causes progressive sensory and autonomic neuropathy with a poor prognosis if untreated. TTR-related cardiomyopathy involves amyloid deposition in the heart, resulting in heart failure. The NEURO-TTRansform trial methodology provides a robust framework for evaluating the efficacy and safety of Eplontersen in patients with ATTRv-PN and ATTR-CM. The detailed assessment of both clinical outcomes and pharmacokinetics contributes to understanding Eplontersen’s potential as a transformative therapy for this patient population. Recent treatment advancements include eplontersen that reduces TTR production by targeting TTR mRNA, effectively preventing amyloid fibril formation. Clinical trials, such as the NEURO-TTRansform study, demonstrated significant efficacy: eplontersen led to an adjusted mean reduction in serum TTR levels of -81.7% compared to placebo, along with improvements in neuropathy impairment (mNIS+7 score change of -24.8, P < 0.001) and quality of life (Norfolk...
Read More
Posted by admin on Apr 30, 2025 in |
Alzheimer’s disease (AD) is an irrevocable most run-of-the-mill neurodeteriorating disease which comprises of lapses in the memory due to the disfigurement of synapse & neurons that leads to numerous types of dementia. As per the outline via (WHO) ICD-10 Mental & Behavioural Classification of Dementia, AD is persuaded by distinctive peculiarities of encephalon by either accretion of Amyloid-β, Neurofibrillary tangles, Insulin Resistance or Free radical generation. On top of that, genetic alteration in TREM-2 modified macrophages in encephalon depicts vast clinical manifestations according to different scalings with scorings. These scores are given by dint of the symptoms evinced with the help of newly retrieve diagnosis markers to prevent the wild mood disorder complications alongside rare organ failures. The numerous methodologies are great headways that makes a grateful resulting impact in the field of AD. Ahead of the times information & a wholistic perspective towards holistic malady can make a great avenue to recuperate in bucket of psychogenic...
Read More
Posted by admin on Apr 30, 2025 in |
The use of biosensors and devices as instruments for health, education, and prevention has garnered a lot of attention in recent years. Personalized therapy depends on accurate and timely monitoring of biological markers and drug effectiveness, which is made feasible by biosensing devices in medications. The creation of the first real biosensor for oxygen sensing touches on the idea of biosensors. The “Web of Science” database had over 84,000 articles regarding “biosensors” between 2005 and 2015. Today, the field of research connects the foundations of electronics, micro/nanotechnology, applied medicine, and the basic sciences (physics, chemistry, and biology). The three primary components of a biosensor a bioreceptor, a transducer, and a signal processing system as well as the principles behind the various biosensor types are the main topics of the review. Additionally, the paper outlines several instances of biosensors being utilized to treat a range of illnesses, including infectious infections, diabetes mellitus, cardiovascular disease, and Alzheimer’s disease. Biosensors have several uses, many of which are intended to improve people’s quality...
Read More
Posted by admin on Apr 30, 2025 in |
Artificial intelligence (AI) is rapidly transforming the drug development process, offering innovative solutions to streamline and accelerate the discovery of new therapeutics. Traditionally, drug development has been a time-consuming and costly endeavor, often taking over a decade and billions of dollars to bring a drug to market. AI, with its ability to analyze vast amounts of complex data, has the potential to significantly reduce both time and costs while improving the success rate of new drugs. AI techniques, including machine learning (ML), deep learning (DL), and natural language processing (NLP), are being integrated at various stages of the drug development pipeline. In the early stages, AI is used to analyze large datasets, such as chemical, genomic, and proteomic data, to identify potential therapeutic targets and biomarkers. Machine learning algorithms can also predict a compound’s biological activity, optimizing lead compounds and enhancing virtual screening compared to traditional methods. Advanced AI methods, such as generative models and reinforcement learning, are being applied to design new molecules with desired properties, improving drug...
Read More
